RE: Daily Mail Transform article4 May 2024 08:23
Hi Serendipity,
We should be pushing on an open door w.r.t. Transform. Key participants (like the two Profs we have mentioned) will be aware of the test and its potential, but that does not ensure participation.
It is a fact that OBD missed the initial round of applications which preceeded commercial availability of PSE. The good news is that the project design specifically anticipates new developments and participants. The bad news is that only a few months ago we were subjected to the charade of Burrow's reading a crib sheet of extracts from the Prostate Cancer UK press release in a vain attempt to appear knowledgeable about the project and opportunity. He says participation is crucial, but his actions do not match those words. We know, for example , that Burrows prioritises the US market (exponential growth via P2P marketing) and that his newest VP's are tasked with getting CIRT and PSE into US medical guidance notes as their #1 priority. Beyond stating that they have employed a 3rd party lobbyist to try to secure participation in Transform they are silent as to who internally is responsible to ensure it happens. Furthermore there are other liquid biopsy tests that use genetic markers already openly discussed by the project sponsors. Stockholm3 is clearly the leading candidate in this research segment and the budget available to differentiate between blood tests may be very limited given the recent emergence of alternatives based on saliva (for example)..